CDP-CHOLINE REDUCES DOPAMINERGIC CELL LOSS INDUCED BY MPP⁺ AND GLUTAMATE IN PRIMARY MESENCEPHALIC CELL CULTURE

REFERENCES

• Adibhatla R. M., Hatcher J. F. Cytidine 5′-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochemical Research 2005; 30(1)15–23
   Google Scholar
• Adibhatla R. M., Hatcher J. F., Dempsey R. J. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 2001; 32(10)2376–2381
   PubMed Web of Science ®Google Scholar
• Adibhatla R. M., Hatcher J. F., Dempsey R. J. Citicoline: Neuroprotective mechanisms in cerebral ischemia. Journal of Neurochemistry 2002; 80(1)12–23
   PubMed Web of Science ®Google Scholar
• Adibhatla R. M., Hatcher J. F., Dempsey R. J. Phospholipase A2, hydroxyl radicals, and lipid peroxidation in transient cerebral ischemia. Antioxidants & Redox Signaling 2003; 5(5)647–654
   PubMed Web of Science ®Google Scholar
• Adibhatla R. M., Hatcher J. F., Larsen E. C., Chen X., Sun D., Tsao F. H. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: Phosphocholine cytidylyltransferase after stroke. Journal of Biological Chemistry 2006; 281(10)6718–6725
   Google Scholar
• Agnoli A., Ruggieri S., Denaro A., Bruno G. New strategies in the management of Parkinson's disease: A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology 1982; 8(6)289–296
   Google Scholar
• Agut J., Font E., Sacristan A., Ortiz J. A. Bioavailability of methyl-14 C CDP-choline by oral route. Arzneimittel-Forschung 1983; 33(7A)1045–1047
   Google Scholar
• Anderson C. M., Swanson R. A. Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. Glia 2000; 32(1)1–14
   PubMed Web of Science ®Google Scholar
• Barrachina M., Dominguez I., Ambrosio S., Secades J., Lozano R., Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated SH-SY5Y human neuroblastoma cells. Journal of the Neurological Sciences 2003; 215(1–2)105–110
   Google Scholar
• Barrachina M., Secades J., Lozano R., Gomez-Santos C., Ambrosio S., Ferrer I. Citicoline increases glutathione redox ratio and reduces caspase-3 activation and cell death in staurosporine-treated SH-SY5Y human neuroblastoma cells. Brain Research 2002; 957(1)84–90
   Google Scholar
• Baskaya M. K., Dogan A., Rao A. M., Dempsey R. J. Neuroprotective effects of citicoline on brain edema and blood-brain barrier breakdown after traumatic brain injury. Journal of Neurosurgery 2000; 92(3)448–452
   Google Scholar
• Brana C., Benham C., Sundstrom L. A method for characterising cell death in vitro by combining propidium iodide staining with immunohistochemistry. Brain Research Brain Research Protocols 2002; 10(2)109–114
   Google Scholar
• Conant R., Schauss A. G. Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: A review of the literature. Alternative Medicine Review 2004; 9(1)17–31
   Google Scholar
• Crespo D., Megias M., Fernandez-Viadero C., Verduga R. Chronic treatment with a precursor of cellular phosphatidylcholine ameliorates morphological and behavioral effects of aging in the mouse [correction of rat] hippocampus. Annals of the New York Academy of Sciences 2004; 1019: 41–43
   PubMed Web of Science ®Google Scholar
• Eberhardt R., Birbamer G., Gerstenbrand F., Rainer E., Traegner H. Citicoline in the treatment of Parkinson's disease. Clinical Therapeutics 1990; 12(6)489–495
   Google Scholar
• Galletti P., De Rosa M., Cotticelli M. G., Morana A., Vaccaro R., Zappia V. Biochemical rationale for the use of CDPcholine in traumatic brain injury: pharmacokinetics of the orally administered drug. Journal of the Neurological Sciences 1991; 103(Suppl)S19–S25
   Google Scholar
• Gille G., Radad K., Reichmann H., Rausch W. D. Synergistic effect of alpha-dihydroergocryptine and L-dopa or dopamine on dopaminergic neurons in primary culture. Journal of Neural Transmission 2006; 113(10): 1383–1393
   Google Scholar
• Grieb P., Gadamski R., Wojda R., Janisz M. CDP-choline, but not cytidine, protects hippocampal CA1 neurones in the gerbil following transient forebrain ischaemia. Folia Neuropathologica 2001; 39(3)141–145
   Google Scholar
• Grieb P., Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. Journal of Neuroscience Research 2002; 67(2)143–148
   Google Scholar
• Hurtado O., Moro M. A., Cardenas A., Sanchez V., Fernandez-Tome P., Leza J. C., Lorenzo P., Secades J. J., Lozano R., Davalos A., Castillo J., Lizasoain I. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiology of Disease 2005; 18(2)336–345
   Google Scholar
• Kent C., Carman G. M. Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Trends in Biochemical Sciences 1999; 24(4)146–150
   PubMed Web of Science ®Google Scholar
• Krupinski J., Ferrer I., Barrachina M., Secades J. J., Mercadal J., Lozano R. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology 2002; 42(6)846–854
   Google Scholar
• Krupinski J., Slevin M., Badimon L. Citicoline inhibits MAP kinase signalling pathways after focal cerebral ischaemia. Neurochemical Research 2005; 30(8)1067–1073
   Google Scholar
• Lipton S. A., Rosenberg P. A. Excitatory amino acids as a final common pathway for neurologic disorders. New England Journal of Medicine 1994; 330(9)613–622
   PubMed Web of Science ®Google Scholar
• Lopez Gx˙ -C., Agut J., Ortiz J. A., Wurtman R. J. Effects of orally administered cytidine 5′-diphosphate choline on brain phospholipid content. Journal of Nutritional Biochemistry 1992; 3(6)313–315
   Google Scholar
• McDaniel M. A., Maier S. F., Einstein G. O. “Brain-specific” nutrients: A memory cure?. Nutrition 2003; 19: 11–12; 957–975
   Google Scholar
• Meldrum B. S. The glutamate synapse as a therapeutical target: Perspectives for the future. Progress in Brain Research 1998; 116: 441–458
   PubMedGoogle Scholar
• Mir C., Clotet J., Aledo R., Durany N., Argemi J., Lozano R., Cervos-Navarro J., Casals N. CDP-choline prevents glutamate-mediated cell death in cerebellar granule neurons. Journal of Molecular Neuroscience 2003; 20(1)53–60
   Google Scholar
• Savci V., Wurtman R. J. Effect of cytidine on membrane phospholipid synthesis in rat striatal slices. Journal of Neurochemistry 1995; 64(1)378–384
   PubMed Web of Science ®Google Scholar
• Secades J. J., Frontera G. CDP-choline: Update and review of its pharmacology and clinical use. Methods and Findings in Experimental and Clinical Pharmacology 2002; 24: 1–53
   Google Scholar
• Teather L. A., Wurtman R. J. Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learning and Memory 2005; 12(1)39–43
   Google Scholar
• Weiss G. B. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sciences 1995; 56(9)637–660
   Google Scholar